Article
作者: Tural, Deniz  ; Yalçın, Şuayip  ; Artaç, Mehmet  ; Ökten, İlker Nihat  ; Cicin, İrfan  ; Yildirim, Mahmut Emre  ; Arslan, Çağatay  ; Alacacioglu, Ahmet  ; Dane, Faysal  ; Gumus, Mahmut  ; Öven, Başak  ; Bozkurt, Oktay  ; Şendur, Mehmet Ali Nahit  ; Karabulut, Bülent  ; Çubukçu, Erdem  ; Harputluoğlu, Hakan  ; Geredeli, Çağlayan  ; Ozcelik, Melike  ; Çelik, Sinemis  ; Açıkgöz, Özgür  ; Karadurmuş, Nuri  ; Türk, Hacı Mehmet  ; Tanrikulu, Eda  ; Sakin, Abdullah  ; Kefeli, Umut  ; Urakçı, Zuhat  ; Karaca, Mustafa  ; Çil, Timucin  ; Bilir, Cemil 
Backgrounds and Objectives:Colorectal cancer is one of the leading causes of mortality both globally and in our country. In Turkey, we conducted a multicenter investigation into the effectiveness of second-line treatments and real-life data for patients with RAS wild-type metastatic colorectal cancer (NCT04757311).
 Materials and Methods:In this retrospective analysis, records from 28 centers were collected, and histopathological, molecular, and clinical characteristics were documented. Patients were categorized into groups based on their second-line biological treatments: anti-EGFR (Group A and Group B, panitumumab and cetuximab) and anti-VEGF (Group C, bevacizumab and aflibercept). They were then compared within these groups.
 Results:
              A total of 588 patients with documented RAS wild-type status were evaluated. The median OS was 15.7, 14.3 and 14.7 months in Group A, Group B and Group C, respectively (
              p
                =  0.764). The median PFS of the patients in second-line setting that received panitumumab, cetuximab and bevacizumab/aflibercept were 7.8, 6.6 and 7.4 months, respectively (
              p
                =  0.848).
            
 Conclusion:According to the results of our real-life data study, there is no significant difference in efficiency between the combination of biological agent and chemotherapy used in the second-line treatments.